FAIRFIELD, Conn., March 15, 2012 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQX:CTTC) today reconfirmed that the growing interest in its Calmare® Scrambler Therapy™ medical device is a function of the universal goal of finding new and innovative methods of treating chronic pain. The Calmare device is noninvasive and avoids habit-forming drugs.
Last June, the Institute of Medicine of the National Academies ("IOM") published its report, "Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research," which highlighted the staggering numbers of Americans -- at least 116 million adults -- experiencing chronic pain, at an even more staggering cost to society -- between $560 billion and $635 billion annually. In the ensuing nine months, there has been an explosion of interest in finding solutions for this growing epidemic, both in the United States and internationally.
Last month, the Senate Committee on Health, Education, Labor, and Pensions chaired by Senator Thomas Harkin (D-IA) held a hearing "Pain in America: Exploring Challenges to Relief," to learn more about the issue. Sen. Harkin stated emphatically, "We need to find new, innovative therapies that we don't know about." (The full hearing is available for viewing at http://www.help.senate.gov/hearings/hearing/?id=5906d585-5056-9502-5dd1-1d549d0d88f7.)
CTTC has one of those revolutionary new therapies in its Calmare® Scrambler Therapy medical device which has been shown to successfully treat neuropathic and cancer related pain without the harmful side effects of powerful pain medications.
News coverage about the benefits Calmare offers is expanding. Earlier this week, Providence, RI-based NBC 10 WJAR's health reporter, Barbara Morse Silva, filmed a story at the new West Warwick, RI Calmar Pain Relief clinic (http://www.cprcenters.com/) featuring a number of patients from around the country who have been successfully treated there with CTTC's Calmare medical device. These patients, desperate for relief from their debilitating pain, came to Dr. Stephen D'Amato's Rhode Island clinic from as far away as Nevada and Michigan as well as from the local area. Suffering from cancer pain, chemotherapy-induced peripheral neuropathy (CIPN) and other forms of chronic neuropathic pain, the patients were all helped by the Calmare device. (See the story which aired March 13 online at: http://www2.turnto10.com/lifestyles/2012/mar/13/health-check-chronic-pain-treatment-ar-963406/.)
About Competitive Technologies, Inc.
Competitive Technologies is a global leader in developing and commercializing innovative products and technologies. CTTC is multifaceted, providing distribution, patent and technology transfer, sales and licensing services. CTTC's staff is focused on the needs of customers and matching those requirements with commercially viable products or technology solutions.
CTTC is the licensed worldwide distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical "Scrambler Therapy™" technology developed in Italy by CTTC's client, Professor Giuseppe Marineo to treat neuropathic pain, including cancer pain. The Calmare® device is currently being manufactured for sale by CTTC's partner, GEOMC Co., Ltd. of Seoul, Korea. For more information on the device, visit www.calmarett.com. Visit CTTC's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2010, filed with the SEC on October 27, 2010, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.